At odds with that observed in animal models, where AIM2 inflammasome activation might contribute to inflammation and progression of NAFLD to NASH [32,33], we could not confirm this observation in humans: in NAFLD and NASH subjects, liver expression of AIM2 was negligible. Here, AIM2 is linked to metabolic dysfunction-associated steatohepatitis.